We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Apax Partners Leads Spin-Out of Biomarker Discovery Company Sense Proteomic
News

Apax Partners Leads Spin-Out of Biomarker Discovery Company Sense Proteomic

Apax Partners Leads Spin-Out of Biomarker Discovery Company Sense Proteomic
News

Apax Partners Leads Spin-Out of Biomarker Discovery Company Sense Proteomic

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Apax Partners Leads Spin-Out of Biomarker Discovery Company Sense Proteomic"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sense Proteomic Ltd. has announced its spin out and its creation as a biomarker discovery company. It will now be focusing on using its proprietary protein array platform to discover novel panels of auto-antibody biomarkers in cancer and autoimmune diseases.

Sense Proteomic was previously a subsidiary of the biosciences tools business Procognia Ltd, whose other subsidiary was listed on the Tel-Aviv stock exchange in 2007.

Commenting on the deal, Amos Goren, of Apax, said, “Apax is pleased to be supporting the new management team of Sense Proteomic as they develop this exciting business. It is our belief that over the next few years growth in the diagnostic industry will revolutionize healthcare by enabling earlier and more targeted treatment of disease.”

Rachel Fallon Joint CEO said, “Apax’s support will allow us to accelerate our biomarker programmes to validate the strong data we already have in both autoimmune diseases and cancer. This will allow us to maintain our position as leaders in the field.”

Chris Lyddon, Sense Proteomic’s other Joint CEO, added “I am delighted that Apax has invested in Sense Proteomic, their support endorses both our technical approach and our business model”.

Advertisement